>>> Up
* ASM Intl Raised to Overweight at Barclays; PT 600 euros
* EasyJet Raised to Outperform at RBC; PT 650 pence
* Hiscox Raised to Buy at Jefferies; PT 1,500 pence
* Hiscox Raised to Buy at Jefferies; PT 1,500 pence
* SOL PT Raised to 49 euros from 41 euros at Berenberg
* Tecnicas Reunidas Raised to Add at AlphaValue/Baader
* Technoprobe Raised to Buy at Deutsche Bank; PT 9 euros
* UBS Raised to Buy at Jefferies; PT 37 Swiss francs
>>> Down
* ASML Cut to Equal-Weight at Barclays; PT 650 euros
>>> Down
* ASML Cut to Equal-Weight at Barclays; PT 650 euros
* Blueprint Medicines Cut to Hold at TD Cowen; PT $130
* Blueprint Medicines Cut to Market Perform at Citizens
* Cemex ADRs Cut to Market Perform at Itau BBA; PT $7.50
* Faron Pharma Cut to Reduce at Inderes; PT 253.32 pence
* Gerresheimer Cut to Hold at Deutsche Bank; PT 58 euros
* Gerresheimer Cut to Hold at Bankhaus Metzler; PT 50 euros
* GSK Cut to Hold From Buy by Berenberg
* GSK ADRs Cut to Hold at Berenberg; PT $41
* Kering Cut to Reduce at AlphaValue/Baader
* Poste Italiane Cut to Equal-Weight at Morgan Stanley
* Rio Tinto ADRs Cut to Hold at Jefferies; PT $63
* Soitec Cut to Hold at Berenberg; PT 50 euros
* *Yubico Cut to Hold From Buy by Berenberg, Target Cut to SEK160.00 From SEK270.00
>>> Initiation
>>> Initiation
* Alter Ego Media S.A Rated New Overweight at Euroxx Securities
* Booking Reinstated Buy at William O'Neil
* Elis Rated New Buy at Jefferies; PT 30 euros
* Emilshus Rated New Buy at Nordea; PT 60 kronor
* Fonciere Inea Rated New Outperform at Oddo BHF; PT 42 euros
* Harbour Energy Rated New Neutral at SpareBank; PT 210 pence
* Harbour Energy Rated New Neutral at SpareBank; PT 210 pence
* Reckitt ADRs Rated New Outperform at BNPP Exane; PT $17.30
* Safran Rated New Outperform at Haitong Intl; PT 296.64 euros
* Uranium Energy Rated New Outperform at BMO; PT $7.75
>>> Call
* Deutsche Bank Raises S&P 500 Target to 6,550 After Cutting It
>>> Call
* Deutsche Bank Raises S&P 500 Target to 6,550 After Cutting It
* Elis Gets Another Buy as Jefferies Sees Compelling Growth Ahead
* GSK Downgraded to Hold at Berenberg as Awaits Product Roll-Outs
* UBS Reaching Turning Point on Capital, Jefferies Upgrades to Buy